Board of Pharmacy by Broaddus, W.
REGULATORY AGENCY ACTION 
losing control over the examination. The 
Board plans to address this issue at a future 
meeting. 
FUTURE MEETINGS: 
August 21-22 in Sacramento. 
November 20-21 in Los Angeles. 
BOARD OF PHARMACY 
Executive Officer: Patricia Harris 
(916) 445-5014 
Pursuant to Business and Professions 
Code section 4000 et seq., the Board of 
Pharmacy grants licenses and permits to 
pharmacists, pharmacies, drug manufac-
turers, wholesalers and sellers of hypoder-
mic needles. It regulates all sales of 
dangerous drugs, controlled substances 
and poisons. The Board is authorized to 
adopt regulations, which are codified in 
Division 17, Title 16 of the California 
Code of Regulations (CCR). To enforce its 
regulations, the Board employs full-time 
inspectors who investigate accusations 
and complaints received by the Board. 
Investigations may be conducted openly 
or covertly as the situation demands. 
The Board conducts fact-finding and 
disciplinary hearings and is authorized by 
law to suspend or revoke licenses or per-
mits for a variety of reasons, including 
professional misconduct and any acts sub-
stantially related to the practice of phar-
macy. 
The Board consists of ten members, 
three of whom are public. The remaining 
members are pharmacists, five of whom 
must be active practitioners. All are ap-
pointed for four-year terms. 
MAJOR PROJECTS: 
Attorney General Issues Opinion 
Regarding Out-of-State Pharmacies. On 
March 3, the Attorney General's Office 
filed Opinion No. 91-305, responding to 
the following three questions submitted 
by Assemblymember Tricia Hunter: (]) 
whether California laws governing phar-
macies apply to out-of-state mail order 
pharmacies which fill prescriptions and 
mail them to people in California; (2) 
whether California's current regulation of 
out-of-state mail order pharmacies is con-
sistent with the commerce clause of the 
U.S. Constitution; and (3) under Califor-
nia law, whether a generic type drug listed 
on the negative drug formulary estab-
lished by the Director of Health Services 
may be substituted for a brand name drug 
by an out-of-state pharmacy when filling 
prescriptions and mailing them to people 
in California. { 11:3 CRLR 101) 
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The opinion answered all three ques-
tions affirmatively, under specified condi-
tions. Regarding the first question, the 
Attorney General noted that Business and 
Professions Code section 4084.6 prohibits 
an out-of-state pharmacy from doing busi-
ness in California unless it obtains an out-
of-state distributor's license from the 
Board of Pharmacy, or is registered with 
the Board as a nonresident pharmacy. Out-
of-state drug distributors are required by 
law to comply with Chapter 9 of the Busi-
ness and Professions Code, which con-
tains most of the statutes that govern phar-
macies in California, and Division 21 of 
the Health and Safety Code. Nonresident 
pharmacies must comply with Business 
and Professions Code sections 4050.1 and 
4383, and Health and Safety Code section 
11164. Thus, the opinion concluded that 
California laws do apply in limited cir-
cumstances to out-of-state pharmacies 
which fill prescriptions and mail them to 
people in California; the extent of their 
applicability depends on how the par-
ticular pharmacy is licensed. 
Regarding California's regulation of 
out-of-state pharmacies, the Attorney 
General noted that in determining whether 
a state-created impact on interstate com-
merce falls within permissible bounds, the 
U.S. Supreme Court established a 
"balancing test" in Pike v. Bruce Church 
lnc., 397 U.S. 137, 142 (1970). Under that 
test, where the statute regulates evenhan-
dedly to effectuate a legitimate local 
public interest, and its effects on interstate 
commerce are only incidental, it will be 
upheld unless the burden imposed on such 
commerce is clearly excessive in relation 
to the putative local benefits. According to 
the opinion, a local purpose which has 
traditionally been favored by the Court is 
one promoting the health and safety of a 
state's inhabitants. Based on its findings 
that the state will be given considerable 
latitude given the subject matter of the 
regulation, the laws are applied indis-
criminately to in- and out-of-state phar-
macies, and the burden on interstate com-
merce is "clearly minimal in relation to the 
legitimate state purpose of protecting the 
health and welfare of California resi-
dents," the Attorney General's Office con-
cluded that California's regulation of out-
of-state pharmacies does not offend the 
Commerce Clause. 
Regarding the third question, the At-
torney General noted that, with certain 
exceptions and qualifications, Business 
and Professions Code section 4047.6 al-
lows a pharmacist to substitute a generic 
drug for a brand name drug when filling a 
prescription. Business and Professions 
Code section 4047.7 provides that one 
such exception applies when the generic 
drug type or drug product has been listed 
on the "negative drug formulary" by the 
Director of the Department of Health Ser-
vices (OHS); if a drug is listed by the OHS 
Director on the negative drug formulary, a 
pharmacist may not substitute it for a 
brand name drug. The Attorney General 
found that compliance with section 
4047.7 is required of all pharmacies in 
California and any pharmacy licensed as 
an out-of-state drug distributor pursuant to 
Business and Professions Code section 
4084.6. However, because pharmacies 
registered as nonresident pharmacies need 
comply only with Business and Profes-
sions Code sections 4050.1 and 4383 and 
Health and Safety Code section 11164 in 
order to maintain their registration and do 
business in California, pharmacies 
registered as nonresident pharmacies may 
substitute a generic type drug listed on the 
negative drug formulary established by 
the OHS Director for a brand name drug 
when filling prescriptions and mailing 
them to people in California. According to 
the opinion, however, no drug is currently 
listed on the negative drug formulary. 
FDA Clarifies Policy Regarding New 
Drug Repacking. Last July, the Board 
sought clarification of the U.S. Food and 
Drug Administration's (FDA) Com-
pliance Policy Guide (CPG) 7132c.06, 
which states that "each step in the 
manufacture and processing of a new drug 
or antibiotic, from handling of raw in-
gredients to final packaging, must be ap-
proved by FDA, whether carried out by 
the original manufacturer or by some sub-
sequent handler or repacker of the 
product. Pharmacists are not exempt from 
these statutory requirements; however, the 
agency regards mixing, packaging, and 
other manipulations of approved drug 
[sic] by licensed pharmacists, consistent 
with the approved labeling of the product, 
as an approved use of the product if con-
ducted within the practice of pharmacy, 
i.e., filling prescriptions for identified 
patients." The Board asked FDA to clarify 
whether "the breaking down of bulk drugs 
for prescription or known need" con-
stitutes manufacturing. Specifically, the 
Board asked whether manipulation by a 
pharmacist of an FDA-approved drug 
constitutes manufacturing (which requires 
registration as a manufacturer) when"(]) 
it is contrary to the manufacturer's pack-
age insert, or (2) it is prepared for a 
specific patient in advance, but in an-
ticipation of, a prescription, or (3) it is 
prepared in anticipation of receiving one 
or more prescriptions for the product, as 
manipulated, but for a specific patient." 
{12:1 CRLR 91; 11:4 CRLR 104) 
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In March, the FDA issued CPG 
7132. 16, entitled "Manufacture, Distribu-
tion, and Promotion of Adulterated, 
Misbranded, or Unapproved New Drugs 
for Human Use by State-Licensed Phar-
macies," in which it clarified its position 
on compounding by a pharmacy that is not 
pursuant to a specific prescription. FDA 
recognized that a licensed pharmacist may 
compound drugs extemporaneously after 
receipt of a valid prescription for an in-
dividual patient, and stated that "[p]har-
macies that do not otherwise engage in 
practices that extend beyond the limits set 
forth in this CPG may prepare drugs in 
very limited quantities before receiving a 
valid prescription, provided they can 
document a history of receiving valid 
prescriptions that have been generated 
solely within an established professional 
practitioner-patient-pharmacy relation-
ship, and provided further that they main-
tain the prescription on file for all such 
products dispensed at the pharmacy as 
required by state law." 
However, FDA stated that it may, in the 
exercise of its enforcement discretion, in-
itiate federal enforcement actions against 
entities and responsible persons when the 
scope and nature of a pharmacy's activity 
raises the kinds of concerns normally as-
sociated with a manufacturer and result in 
significant violations of the new drug, 
adulteration, or misbranding provisions of 
the Federal Food, Drug, and Cosmetic 
Act. In general, the FDA will consider the 
following factors in determining whether 
compounding by a pharmacy constitutes 
manufacturing: whether the pharmacy ad-
vertises and solicits business from 
prescribers and/or patients; whether the 
pharmacy compounds more than it should 
expect to use based on existing relation-
ships and demands from prescribers; 
whether there is an inordinate volume of 
bulk drugs ordered or compounded drugs 
dispensed compared to existing orders; 
and whether the pharmacy manufactures 
products that are readily available com-
mercially or manufactures what are-in 
effect-unapproved new drugs that vary 
more than slightly from an FDA-approved 
drug that is commercially available. 
At its March meeting, the Board 
reviewed FDA's new guide and found it 
consistent with its own positions. 
Patient Consultation Regulations. In 
August 1990, the Office of Administrative 
Law (OAL) approved the Board's adop-
tion of new sections 1707 .1 and 1707 .2, 
Di vision 17, Title 16 of the CCR, which 
requires pharmacists to maintain patient 
medication profiles for all ongoing 
patient-consumers and to provide an oral 
consultation to each patient or patient's 
agent whenever a new prescription is dis-
pensed, with specified exceptions. Al-
though the regulations were originally 
scheduled to take effect in March 1991, 
the Board delayed the effective date until 
January 1992 in order to provide phar-
macists with additional time to prepare for 
and phase in the changes to pharmacy 
practice mandated by sections 1707. I and 
1707.2.At a special December 1991 meet-
ing, the Board voted to delay the effective 
date of the regulations for a second time, 
in response to claims that-more than one 
year after their original approval-the in-
dustry was still unprepared to implement 
the regulations. [ 12:1 CRLR 91 J 
In order to comply with the Ad-
ministrative Procedure Act, the Board 
adopted an emergency regulation 
suspending the implementation of the 
provisions for 120 days. At its March 18 
meeting, the Board conducted a public 
hearing regarding its decision to change 
the effective date to November I. At that 
hearing, the Board received testimony 
from the California Association of Public 
Hospitals (CAPH) in support of the delay; 
CAPH also advocated tying the effective 
date of the oral consultation regulations to 
the implementation of the pharmacy tech-
nician regulations, suggesting that the 
consultation regulations take effect three 
to six months after the Board's technician 
regulations are approved (see supra}. Fol-
lowing the public hearing, the Board 
adopted the proposed amendments to sec-
tions 1707 .1 and 1707 .2, delaying their 
effective date until November I. The 
Board submitted the rulemaking file to 
OAL on April 21 and is awaiting OAL's 
response. 
Pharmacy Technicians. Pursuant to 
AB 1244 (Polanco) (Chapter 841, Statutes 
of 1991), the Board recently proposed the 
adoption of regulations defining the func-
tions and qualifications of pharmacy tech-
nicians, who may perform packaging, 
manipulative, repetitive, or other nondis-
cretionary tasks while assisting, and while 
under the direct supervision of, a 
registered pharmacist. On January 21, the 
Board conducted a public hearing on its 
proposed amendments to section 1717(c) 
and adoption of new sections 1793-
1793. 7, Division 17, Title 16 of the CCR, 
to define the qualifications and permis-
sible duties of pharmacy technicians. 
Existing section l 7 l 7(c) lists certain 
duties which must be performed by a phar-
macist and those duties which may be 
performed by non-licensed personnel, 
such as typing prescription labels and re-
questing and receiving refill authorization 
subject to prior review by a pharmacist. 
The Board proposes to incorporate por-
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tions of this section into new sections 
1793.1 and 1793.3. Specifically, proposed 
section 1793.1 would list functions which 
only a pharmacist may perform and which 
may not be delegated to a pharmacy tech-
nician; section 1793.2 would identify the 
tasks which a pharmacy technician may 
perform under the direct supervision and 
control of a licensed pharmacist, including 
removing drugs from stock, counting, 
pouring, or mixing pharmaceuticals, plac-
ing the products into a container, affixing 
labels to containers, packaging and 
repackaging; and proposed section 1793.3 
would describe and update tasks which 
may be performed by non-licensed per-
sonnel who are not pharmacy technicians, 
to include the entry of prescriptions into a 
computer record system. 
Proposed section 1793.4 would estab-
lish registration requirements for phar-
macy technicians, and authorize the Board 
to issue a certificate to an applicant who 
has met any of the following require-
ments: has obtained at least an associate 
of arts degree in a field of study directly 
related to the duties performed by a phar-
macy technician; has completed a training 
course specified and approved by the 
Board; is eligible to take the Board's phar-
macist licensure exam; or has one year's 
experience (a minimum of 1,500 hours) 
performing the tasks of a pharmacy tech-
nician while assisting a pharmacist in the 
preparation of prescriptions in specified 
facilities. Section 1793.5 would specify 
the training courses which are acceptable 
to the Board in satisfaction of the require-
ment in section 1793.4. Section 1793.6 
would establish requirements for phar-
macies employing technicians; in par-
ticular, it clarifies that nonpharmacist per-
sonnel must work under the direct super-
vision of a registered pharmacist, the su-
pervising pharmacist must be on the 
premises at all times, and the pharmacist 
must indicate that all prescriptions 
prepared by a technician have been check-
ed by initialing the prescription label 
before the medication is given to the 
patient. The subsection also requires a 
technician to wear identification clearly 
identifying him/her as a technician. 
In response to comments from the in-
dustry, the Board modified its proposed 
language in various significant respects. 
For example, regarding technician 
qualifications, the Board eliminated lan-
guage which would have provided that a 
person shall be deemed to have 
"equivalent experience" if he/she has at 
least three years of experience in a phar-
macy and has passed an examination, as 
specified. Instead, the modified language 
provides that a person shall be deemed to 
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have equivalent experience if he/she has 
at least 1,500 hours of experience per-
forming specified duties in a pharmacy in 
the preceding three years. 
Also, the Board increased from 120 to 
240 the number of hours required to be 
provided by specified technician training 
courses seeking to be approved by the 
Board. In addition, the Board eliminated a 
requirement that such training programs 
provide instruction on the general chemi-
cal and physical properties of drugs hand-
led in a pharmacy. 
The Board approved the language of 
the regulations as modified, and released 
it for a fifteen-day public comment period 
which ended on February 14. Following 
the public comment period and approval 
by the Director of the Department of Con-
sumer Affairs (DCA), the Board sub-
mitted the rulemaking file to OAL on 
April 17. 
Locked Storage and Emergency 
Delivery Requirements for Medical 
Device Retailers. On January 22, the 
Board held a public hearing on its 
proposed adoption of new sections 1748.1 
and 1748.2, Title 16oftheCCR,regarding 
the proper storage of dangerous devices at 
medical device retailer (MOR) retail sites, 
and the delivery of devices by MDRs to 
patients after hours or in emergency situa-
tions. Since July 1991, the Board of Phar-
macy has licensed MDRs as a separate 
class. MDRs are non-pharmacy firms that 
may dispense, upon prescription, 
dangerous devices such as hypodermic 
syringes and other items that are marked 
by the manufacturer as available upon 
prescription only. Each retail site of an 
MOR must have a Board-licensed in-
dividual designated as "in charge." This 
individual may be a pharmacist or an "ex-
emptee," a separately-licensed individual 
authorized to dispense dangerous devices. 
Proposed section 1748. l would pro-
vide that an MOR may use locked storage 
(a lock box or locked area) for the emer-
gency dispensing of dangerous devices. 
Locked storage may be installed or placed 
in a service vehicle of the MOR for pur-
poses of delivery, set-up, or after-hours 
emergency service of dangerous devices 
to patients having prescriptions on file for 
the dangerous device. No hypodermic 
needles or syringes may be stored in this 
locked storage. Section 1748. l would also 
provide that dangerous devices shall be 
furnished from the locked storage only 
upon the oral or written authorization of 
an exemptee to an employee of the MOR 
who operates the service vehicle; the ser-
vice vehicle and the locked storage con-
tained therein shall be locked at all times; 
a current inventory and record of all 
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dangerous devices placed into and fur-
nished from the locked storage shall be 
maintained by the MOR for three years; 
within 72 hours of furnishing a dangerous 
device from the emergency storage, the 
exemptee shall be responsible for check-
ing the contents of the locked storage and 
noting the dangerous devices furnished on 
the inventory; and the exemptee shall be 
responsible for checking the contents of 
the locked storage on a weekly basis. 
Proposed section 1748.2 would permit 
an MOR to keep a dangerous device in a 
retail area of the premises during the ab-
sence of an exemptee, if the device is of 
sufficient size and weight as to make 
removal "difficult." 
At the January 22 hearing, the Board 
received comments urging it to relax 
proposed section 1748. l, which appears to 
limit emergency dispensing from the lock 
box to "prescriptions on file for the 
dangerous devices," and to preclude emer-
gency dispensation for newly-prescribed 
devices. The Board also received requests 
to expand its definition of "exemptees" to 
include licensed health care providers; an 
exemptee is a person, other than a phar-
macist, who is authorized to dispense 
dangerous devices. The Board noted that 
it is authorized to regulate dispensers, not 
health care providers. It further noted that 
OHS and other agencies regulate health 
care providers and home health care agen-
cies, and are responsible for their use of 
dangerous devices for replacement or pur-
suant to a new prescription. The Board 
then adopted the regulations as originally 
proposed. At this writing, the rulemaking 
file awaits review and approval by OAL. 
Partial Filling of Schedule II 
Prescriptions. As originally proposed, 
new section 1745, Title 16 of the CCR, 
would allow partial filling of Schedule II 
controlled substance prescriptions for ter-
minally ill patients who are in chronic 
pain, under certain circumstances. Fol-
lowing a public hearing last October, the 
Board modified its proposed language to 
also allow partial filling when the 
prescription is for an inpatient of a skilled 
nursing facility; the Board released the 
modified text for a fifteen-day comment 
period. [12:1 CRLR 91] During that 
period, the Board received comments 
from the California Medical Association 
( CMA ), which expressed concern over the 
Board's use of the terms "chronic, con-
tinuing pain" and "terminally ill." In 
response to CMA's concerns, the Board 
deleted the chronic pain requirement and 
revised the definition of "terminally ill" to 
mean a patient for whom a licensed 
physician has made and documented a 
diagnosis of illness or disease that will 
result in death. The Board released the 
new language for an additional fifteen-day 
comment period which ended on February 
14. At this writing, the proposed section is 
undergoing legal review prior to being 
submitted to DCA and OAL. 
Part-Time Pharmacist-in-Charge 
Regulation. In 1991, the Board promul-
gated section 1709.1, Title 16oftheCCR, 
which was developed to clarify statutory 
requirements regarding the pharmacist-in-
charge; specifically, the regulation re-
quires that this pharmacist have full 
knowledge of the daily operations of a 
pharmacy and specifies that a pharmacist 
may be pharmacist-in charge at only one 
pharmacy. According to the Board, after 
the regulation took effect, it learned that 
this situation had a negative impact on 
several pharmacies which operate on a 
part-time basis, with non-overlapping 
hours, for which the sole pharmacist at 
each served as pharmacist-in-charge at 
both. To remedy this problem, the Board 
published on April 10 notice of its intent 
to amend section 1709.1 to allow a phar-
macist to be the pharmacist-in-charge at 
two pharmacies if only one of these phar-
macies is open at any given time and if that 
pharmacist is the only pharmacist at each 
pharmacy. [ 12:1 CRLR 91-92]The Board 
was scheduled to conduct a public hearing 
on this amendment on May 27 in 
Sacramento. 
Other Regulatory Action. The follow-
ing regulatory changes are also being pur-
sued by the Board: 
-Licensure of Drug Wholesalers. The 
Board's proposed amendments to section 
1780, which would change California's 
requirements for drug wholesalers so that 
they meet or exceed the standards of the 
federal government under the Prescription 
Drug Marketing Act of 1987, were sub-
mitted to OAL for approval on May 9. 
[11:3 CRLR 101-{)2] 
-Compounding for Office Use. 
Proposed new section 1716. l defines the 
quantity of compounded medication 
which a pharmacist may furnish to a 
prescriber for office use under Business 
and Professions Code section 4046(c)(l). 
Proposed new section 1716.2 specifies the 
minimum types of records that phar-
macies must keep when they furnish com-
pounded medication to prescribers in 
quantities larger than required for the 
prescriber's immediate office use or when 
a pharmacy compounds medication for 
future furnishing. [ 11: 3 CRLR 102 J These 
proposed regulations were also submitted 
to OAL for approval on May 9. 
LEGISLATION: 
SB 2044 (Boatwright), as amended 
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April 2, would declare legislative findings 
regarding unlicensed activity and 
authorize all DCA boards, bureaus, and 
commissions, including the Board of 
Pharmacy, to establish by regulation a sys-
tem for the issuance of an administrative 
citation to an unlicensed person who is 
acting in the capacity of a licensee or 
registrant under the jurisdiction of that 
board, bureau, or commission. [A. 
CPGE&ED} 
AB 3415 (Tucker), as amended May 7, 
would exclude from the definition of 
"dangerous devices" any prosthetic or or-
thopedic devices that do not require a 
prescription. This bill would also delete an 
existing provision of Jaw which requires 
that any retailer who sells prosthetic or 
orthotic dangerous devices on the 
premises have a prescribed fitting room 
under certain circumstances. [S. B&PJ 
AB 3286 (Tucker), as amended May 
13, would permit a medical device retailer 
to dispense, furnish, transfer, or sell a 
dangerous device to a licensed physical 
therapist. [A. Floor] A similar bill, AB 
2379 (Baker), was dropped by its author. 
AB 2638 (Boland), as amended May 
13, would exempt a chiropractor acting 
within the scope of his/her license from 
prohibitions against furnishing dangerous 
drugs or devices. This bill would also pro-
vide that a medical device retailer may 
dispense, furnish, transfer, or sell a 
dangerous device to a licensed chiroprac-
tor. [A. Floor} 
AB 2525 (Brown), as amended April 
22, and SB 1418 (Moore), as amended 
April 28, would each establish the Clean 
Needle and Syringe Exchange Pilot 
Project, and would authorize pharmacists, 
physicians, and certain persons authorized 
under the pilot project to furnish hypoder-
mic needles and syringes without a 
prescription or permit as prescribed 
through the pilot project. {A. Floor, S. 
Floor; respectively J 
SB 1986 (Marks), as introduced 
February 21, would prohibit disability in-
surers that provide coverage for phar-
maceutical services from requiring their 
insureds or persons covered by the policy 
to obtain pharmaceutical services ex-
clusively from nonresident pharmacies, 
and would provide that insurers may not 
impose any limitations on coverage of 
pharmaceutical services provided by in-
state pharmacies that are not also imposed 
on nonresident pharmacies. [S. 
InsCl&Corps] 
AJR 63 (Bronzan), as amended May 
7, would urge the President and Congress 
to authorize the FDA to investigate a new 
transitional drug category available only 
through licensed pharmacists, with the 
goal to decrease the time needed for the 
FDA to approve a drug for over-the-
counter status. [A. Health} 
AB 3133 (Hunter), as amended April 
27, would specify that no provision of law 
prohibits the sale of dangerous devices to 
licensed home health agencies and 
licensed hospices, as defined. [S. B&P J 
AB 2743 (Lancaster), as amended 
April 9, would amend Business and 
Professions Code section 4038 to delete 
the exemption of pharmacies and licensed 
manufacturers from the definition of the 
term wholesaler. [A. Floor} 
AB 2070 (lsenberg), as amended 
August 19, would generally make it un-
lawful for specified healing arts licensees 
to refer a person to any laboratory, phar-
macy, clinic, or health care facility solely 
because the licensee has an ownership in-
terest in the facility. However, a licensee 
could make those referrals if the person 
referred is the licensee's patient ofrecord, 
there is no alternative provider or facility 
available, and the licensee certifies that to 
delay or forego the referral would cause 
an unneeded health risk to the patient. [S. 
Rules] 
SB 664 (Calderon). Existing law 
prohibits pharmacists, among others, from 
charging, billing, or otherwise soliciting 
payment from any patient, client, cus-
tomer, or third-party payor for any clinical 
laboratory test or service if the test or 
service was not actually rendered by that 
person or under his/her direct supervision, 
unless the patient is apprised at the first 
solicitation for payment of the name, ad-
dress, and charges of the clinical 
laboratory performing the service. As 
amended March 12, this bill would also 
make this prohibition applicable to any 
subsequent charge, bill, or solicitation. 
This bill passed both the Senate and the 
Assembly and is currently awaiting 
Senate concurrence in Assembly amend-
ments. 
AB 1226 (Hunter), as amended March 
30, would repeal Business and Profes-
sions Code section 4047.7, which requires 
the Director of the Department of Health 
Services to establish a formulary of 
generic drug types and drug products 
which the Director determines 
demonstrate clinically significant biologi-
cal or therapeutic inequivalence and 
which, if substituted, would pose a threat 
to the health and safety of patients receiv-
ing medication if that medication is sub-
stituted by a pharmacist in lieu of a brand 
name drug prescribed by a prescriber. [S. 
B&PJ 
AB 855 (Hunter). Under existing law, 
registered pharmacists are required to in-
form patients of the harmful effects of the 
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prescnpt10n drugs not previously dis-
pensed to the patient, and to provide a 
label or enclosure with the drug container 
containing certain information. As 
amended May 4, this bill would require 
that a health facility ensure that each of its 
patients receives a consultation from a 
pharmacist, physician, or registered nurse 
regarding medications received at the time 
of discharge. [S. B&PJ 
SB 917 (Kopp) would require certain 
health care service plans that propose to 
offer a pharmacy benefit or change their 
relationship with pharmacy providers to 
give written or published notice to phar-
macy service providers of the plan's 
proposal, and give those providers an op-
portunity to submit a bid to participate in 
the plan's panel of providers on the terms 
proposed. [A. Desk} 
AB 819 (Speier). Existing law general-
ly provides that it is not unlawful for 
prescribed health care professionals to 
refer a person to a laboratory, pharmacy, 
clinic, or health care facility solely be-
cause the licensee has a proprietary inter-
est or co-ownership in the facility. As 
amended January 29, this bill would in-
stead provide that it shall be unlawful for 
these licensed health professionals to refer 
a person to any diagnostic imaging center, 
clinical laboratory, physical therapy or 
rehabilitation facility, or psychometric 
testing facility which is owned in whole or 
in part by the licensee or in which the 
licensee has a proprietary interest, and 
would provide that disclosure of the 
ownership or proprietary interest does not 
exempt the licensee from the prohibition. 
It would, however, permit specified 
licensed health professionals to refer a 
person to such a facility which is owned 
in whole or in part by the licensee or in 
which the licensee has a proprietary inter-
est if the person referred is the licensee's 
patient of record, there is no alternative 
provider or facility available, and to delay 
or forego the needed health care would 
pose an immediate health risk to the 
patient. [S. B&P J 
SB 1033 (Marks), which would have 
permitted pharmacists to manufacture, 
measure, fit to the patient, sell, and repair 
medical devices without regard to whether 
they bear a specified legend relating to a 
federal prohibition against dispensing 
without a prescription, died in committee. 
LITIGATION: 
In People v. Joseph Doss, No. 
8046265 (Apr. I, 1992), the Second Dis-
trict Court of Appeal affirmed the convic-
tion of Doss, a pharmacist and the owner 
of Medical Memorial Pharmacy, for pos-
session for sale of four controlled substan-
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ces. The court noted that the evidence, 
taken in the light most favorable to the 
judgment, established that Doss ordered 
and took possession of large quantities of 
certain controlled substances in high 
dosages; the drugs were of a type rarely 
prescribed by physicians but in high 
demand among the illegal street trade. On 
appeal, Doss contended that evidence was 
legally insufficient to warrant its submis-
sion to the jury and factually insufficient 
to sustain his convictions; Doss also chal-
lenged the trial court's denial of his motion 
to suppress evidence obtained by the state 
Board of Pharmacy inspector during his 
audit of Doss' pharmacy records. 
The Second District noted that "this 
case squarely presents the issue whether a 
pharmacist is immune from prosecution 
for illegal possession of controlled sub-
stances, absent evidence he removed the 
drugs from pharmacy premises." Doss 
contended that Business and Professions 
Code section 4230 immunizes him from 
prosecution because he is a pharmacist 
and there was no evidence he withdrew the 
missing drugs from the pharmacy 
premises; section 4230 provides that "[n]o 
person shall have in possession any con-
trolled substance, except that furnished to 
such person upon the prescription of a 
physician, dentist, podiatrist, or 
veterinarian. The provisions of this sec-
tion do not apply to the possession of any 
controlled substance by a manufacturer or 
wholesaler or a pharmacy or a physician 
or podiatrist or dentist or veterinarian, 
when in stock in containers correctly 
labeled with the name and address of the 
supplier or producer." The court rejected 
Doss' arguments, stating that the "obvious 
purpose of ... section 4230 is to authorize 
the possession for sale of certain control-
led substances by licensed pharmacists, 
on pharmacy premises, to those holding 
valid prescriptions. It does not confer 
blanket immunity on a pharmacist to deal 
drugs illegally from behind the counter or 
to possess them with that intent." Finding 
that section 4230 does not confer blanket 
immunity on a pharmacist to possess con-
trolled substances for any purpose on 
pharmacy premises, the Second District 
found that the case was properly sub-
mitted to the jury. 
Next, the court examined the factual 
sufficiency of the evidence. The 
prosecution's evidence established that 
from January 1987 through April 18, 
1988, Doss' pharmacy ordered from one 
pharmaceutical wholesaler 4,000 tablets 
of Glutethimide (Doriden) in the highest 
dosage available; at least three of the proof 
of delivery slips appeared to bear Doss' 
signature. During that same period, Doss' 
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pharmacy ordered from another 
wholesaler 2,500 Biphetamine, 1,200 
Dilaudid, 2,800 Tuinal, and an additional 
11,500 Glutethimide; these orders were 
also for the strongest dosages available, 
and a number of invoices and driver 
manifests showing delivery of the four 
drugs to Doss' pharmacy appeared to bear 
the signature "J. Doss" as the person ac-
cepting the shipment. On April I 8, 1988, 
following a report from a drug wholesaler 
that Doss' pharmacy had ordered an ex-
cessive amount of Glutethimide, Board of 
Pharmacy inspector Martin Levine con-
ducted an audit of Medical Memorial 
Pharmacy. That audit revealed that the 
pharmacy had no purchase records for 
Glutethimide, Biphetamine, Dilaudid, or 
Tuinal; the pharmacy had no prescriptions 
for the lawful distribution of any of the 
four drugs during the period January 1987 
through April 18; Doss had not performed 
the Drug Enforcement Administration-re-
quired inventory for the period in ques-
tion; and the pharmacy had none of the 
four drugs in stock. Doss provided no 
explanation for the missing drugs, and 
said he was unaware of any thefts from the 
pharmacy during the fifteen-month 
period. 
The Second District found that the jury 
was entitled to conclude from the 
evidence that Doss possessed the four 
controlled substances for the purpose of 
selling them outside the legitimate prac-
tice of his pharmaceutical business. 
Noting the undisputed evidence showing 
that the pharmacy ordered and received 
the drugs and that Doss took possession of 
some of them, that all of the drugs disap-
peared from the pharmacy without a single 
record to account for their lawful distribu-
tion and without any report of a theft or 
burglary, and that the drugs were of a kind 
rarely prescribed by physicians but in 
demand on the street and that Doss was 
aware of such demand, the court con-
cluded that the jury had "more than suffi-
cient evidence to convict defendant on all 
four counts." 
Finally, Doss contended that the trial 
court improperly refused to suppress 
evidence gained from the audit conducted 
by the Board of Pharmacy's inspector on 
April 18, 1988. The trial court denied 
Doss' motion to suppress the results of 
Levine's audit, finding that Doss lacked a 
reasonable expectation of privacy in the 
pharmacy records; the court specifically 
noted that the audit was conducted pur -
suant to Business and Professions Code 
sections 4231 and 4232, which expressly 
authorize warrantless inspections of high-
ly regulated businesses. 
The Second District affirmed the trial 
court's denial of the motion to suppress, 
noting that it is well settled that warrant-
less searches of pervasively regulated and 
licensed businesses are permissible under 
the Fourth Amendment, if conducted pur-
suant to statutory authorization. The 
Second District stated that "[i]t is un-
disputed that pharmacies are closely regu-
lated businesses in California. It is equally 
clear that state statutes authorize ad-
ministrative inspections of pharmacies." 
The court concluded that under both the 
statutory scheme and the circumstances of 
this case, defendant had no reasonable 
expectation of privacy in the pharmacy 
records, and that given the pervasive 
regulation of the pharmaceutical industry 
and Doss' particular familiarity with it, 
there can be no legitimate claim that he 
maintained any expectation of privacy in 
the pharmacy records. 
RECENT MEETINGS: 
At the Board's January meeting, staff 
reported that the Department of Finance 
had approved the following budget 
change proposals, which have been in-
cluded in the Governor's proposed 1992-
93 budget: a $74,000 increase in funding 
to the Pharmacist Recovery Program, the 
Board's diversion program for substance-
abusing licensees; $39,000 to add one 
clerical position to the Licensing Unit to 
process examination applications; 
$45,000 to add one clerical position to the 
Enforcement Unit on a limited-term basis; 
$68,000 to produce an inspector proce-
dure manual; and $145,000 to add one 
Associate Governmental Program Analyst 
and one Office Technician to implement 
the pharmacy technician program, and one 
office assistant to assist in the registration 
of applicants. These changes must be ap-
proved by the legislature in its 1992-93 
budget bill. 
Also at its January meeting, the Board 
heard a presentation from Rebecca Ar-
mato of Integrated Medical Systems, Inc. 
(IMS), regarding the computerized trans-
mission of prescriptions and refill 
authorizations. IMS has developed Rx 
Manager, a software program that allows 
prescription and refill authorizations to be 
transmitted between pharmacies and 
physicians electronically over com-
munication networks. The Board noted its 
March 1990 policy decision stating that it 
believes facsimile transmission of 
prescriptions is legal and subject to the 
same requirements as orally-transmitted 
prescriptions. The Board then created a 
subcommittee to formulate recommenda-
tions regarding proposed regulatory ac-
tions authorizing the electronic transmis-
sion of prescriptions and refill authoriza-
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tions. 
At its March 18-19 meeting, the Board 
discussed the recent recommendation of 
the Legislative Analyst's Office (LAO) to 
abolish all independent boards and 
bureaus within DCA, replace them with 
advisory boards, and consolidate the 
licensing and enforcement functions of 
these agencies into the Department; LAO 
contends that such an action would in-
crease the efficiency and cost-effective-
ness of state regulation of trades and 
professions. (See supra agency reports on 
LAO and DCA for related discussion.) 
Following a discussion, the Board unani-
mously agreed that its enforcement, con-
sumer complaint handling, and licensing 
functions should remain separate from a 
consolidated unit within DCA, due to the 
specialized nature of pharmacy enforce-
ment and the increasingly sophisticated 
nature of pharmacy practice. 
Also at the March meeting, the Board 
discussed a request from the California 
Pharmacists Association (CPhA) to alter 
the Board's enforcement procedure. 
Specifically, CPhA had directed its staff to 
work with Board staff to accomplish the 
following changes: (I) before referral of 
an administrative action against a licensee 
to the Attorney General's Office, Board 
staff would provide an opportunity for the 
licensee to discuss the proposed action 
with Board staff; and (2) Board staff 
would provide notice to the licensee of 
any referral to the Attorney General's Of-
fice. Executive Officer Patricia Harris 
noted that throughout the investigation 
process, every opportunity is given to the 
licensee to provide information to the in-
spector. However, discussion of an inves-
tigation at the supervisory level would 
probably bog down the system, increase 
workload, and further delay an already 
lengthy process. Harris recommended that 
the Board not change the process as to do 
so would be contrary to public policy. The 
Board made no motion to amend its 
process, instead suggesting that the Board 
provide more education and information 
about the enforcement process to alleviate 
licensees' apprehensions without com-
promising investigations and administra-
tive actions. 
FUTURE MEETINGS: 
October 14-15 in Los Angeles. 
BOARD OF REGISTRATION FOR 
PROFESSIONAL ENGINEERS 
AND LAND SURVEYORS 
Executive Officer: Darlene Stroup 
(916) 920-7466 
The Board of Registration for Profes-
sional Engineers and Land Surveyors 
(PELS) regulates the practice of engineer-
ing and land surveying through its ad-
ministration of the Professional Engineers 
Act, sections 6700 through 6799 of the 
Business and Professions Code, and the 
Professional Land Surveyors' Act, sec-
tions 8700 through 8805 of the Business 
and Professions Code. The Board's 
regulations are found in Division 5, Title 
16 of the California Code of Regulations 
(CCR). 
The basic functions of the Board are to 
conduct examinations, issue certificates, 
registrations, and/or licenses, and ap-
propriately channel complaints against 
registrants/licensees. The Board is addi-
tionally empowered to suspend or revoke 
registrations/licenses. The Board con-
siders the proposed decisions of ad-
ministrative law judges who hear appeals 
of applicants who are denied a registra-
tion/license, and those who have had their 
registration/license suspended or revoked 
for violations. 
The Board consists of thirteen mem-
bers: seven public members, one licensed 
land surveyor, four registered Practice Act 
engineers and one Title Act engineer. 
Eleven of the members are appointed by 
the Governor for four-year terms which 
expire on a staggered basis. One public 
member is appointed by the Speaker of the 
Assembly and one by the Senate Rules 
Committee. 
The Board has established four stand-
ing committees and appoints other special 
committees as needed. The four standing 
committees are Administration, Enforce-
ment, Examination/Qualifications, and 
Legislation. The committees function in 
an advisory capacity unless specifically 
authorized to make binding decisions by 
the Board. 
Professional engineers are registered 
through the three Practice Act categories 
of civil, electrical, and mechanical en-
gineering under section 6730 of the Busi-
ness and Professions Code. The Title Act 
categories of agricultural, chemical, con-
trol system, corrosion, fire protection, in-
dustrial, manufacturing, metallurgical, 
nuclear, petroleum, quality, safety, and 
traffic engineering are registered under 
section 6732 of the Business and Profes-
sions Code. 
Structural engineering and geotechni-
cal engineering are authorities linked to 
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the civil Practice Act and require an addi-
tional examination after qualification as a 
civil engineer. 
On February 24, Governor Wilson ap-
pointed Ted Fairfield to serve as the 
Board's civil engineer member. Fairfield, 
founder of a ci vii engineer consulting firm 
in Pleasanton, has been registered as a 
professional civil engineer in California 
since 1962. 
MAJOR PROJECTS: 
Professional Land Surveyor Blue 
Ribbon Panel Controversy. PELS cur-
rently administers its own land surveyor 
examination, which is prepared by CTB 
McMillan/McGraw Hill (CTB) under a 
contract which extends until 1993. In Oc-
tober 1991, PELS passed a motion to 
resume the use-as of April 1993--of the 
national examination prepared by the Na-
tional Council of Examiners for Engineer-
ing and Surveying (NCEES) for purposes 
of licensing land surveyors. The Board 
then appointed a blue ribbon panel of land 
surveyors to review the national examina-
tion and develop a supplemental Califor-
nia-specific exam to be administered with 
the national exam. 
At PELS' February 14 meeting, Board 
member David Slawson indicated that the 
panel would recommend that PELS 
postpone the use of the NCEES profes-
sional land surveyor exam until 1994. In 
the interim, the panel recommended that 
PELS retain the current examination 
prepared by CTB. Following a lengthy 
discussion, the Board tabled the matter 
until its next meeting. 
At its April 17 meeting, PELS resumed 
its discussion regarding the panel's 
recommendation. Additionally, the Board 
discussed the apparently recent revelation 
that many of the blue ribbon panel mem-
bers had worked as subject matter experts 
to develop and grade California's current 
examination sold to the Board by CTB, 
and had received reimbursement for 
travel, lodging, and subsistence in excess 
of $250 within the past twelve months 
from CTB. Based on these facts, Depart-
ment of Consumer Affairs (DCA) legal 
counsel Don Chang opined that it may be 
inappropriate for the Board to consider 
some of the panel's recommendations. 
However, by a vote of 8-4, PELS agreed 
to postpone the implementation of the 
NCEES and the California-specific 
professional land surveyor exam to allow 
for the reorganization and new member-
ship of the blue ribbon panel, and to work 
with NCEES to strengthen its exam; PELS 
agreed to retain the current CTB exam in 
the interim. The Board also directed Ex-
ecutive Officer Darlene Stroup to obtain 
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